Background Fingolimod was approved in 2010 for the treatment of patients with the
relapsing‐remitting (RR) form of multiple sclerosis (MS). It was designed to reduce the …

Background Interferons‐beta (IFNs‐beta) and glatiramer acetate (GA) were the first two
disease‐modifying therapies (DMTs) approved 20 years ago for the treatment of multiple …

Background: Ranking of interventions is one of the most appealing elements of network
meta-analysis. There is, however, little evidence about the reliability of these rankings …

Importance After multiple sclerosis (MS) relapse while a patient is receiving an injectable
disease-modifying drug, many physicians advocate therapy switch, but the relative …

Multiple sclerosis is the most common chronic autoimmune disease of the central nervous
system which preferentially affects females at childbearing age. For this reason, patients and …

Subcutaneous pegylated interferon beta-1a (peginterferon beta-1a [PEG-IFN]) 125 μg every
two or four weeks has been studied in relapsing-remitting multiple sclerosis (RRMS) patients …

Despite recent treatment advances, multiple myeloma (MM) remains incurable and patients
develop a progressively relapsing disease with subsequent poor prognosis. Studies have …

Multiple sclerosis (MS) is a life-long, potentially debilitating disease of the central nervous
system (CNS). MS is considered to be an immune-mediated disease, and the presence of …

Background: It is unclear whether natalizumab and fingolimod have analogous efficacy for
relapsing-remitting multiple sclerosis (RRMS). Objective: To compare the outcome of RRMS …

The diagnosis of multiple sclerosis (MS) is dependent on the presence of clinical and
paraclinical evidence demonstrating dissemination of central nervous system lesions in both …